Entering text into the input field will update the search result below

Iovance Biotherapeutics, Inc. (IOVA) CEO Maria Fardis on Q1 2021 Results - Earnings Call Transcript

SA Transcripts profile picture
SA Transcripts

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q1 2021 Earnings Conference Call May 6, 2021 4:30 PM ET

Company Participants

Maria Fardis - Chief Executive Officer & President

Friedrich Finckenstein - Chief Medical Officer

Jean Marc Bellemin - Chief Financial Officer

Sara Pellegrino - Vice President, Investor and Public Relations

Jim Ziegler - Senior Vice President, Commercial

Conference Call Participants

Michael Yee - Jefferies LLC

Peter Lawson - Barclays Bank

Mark Breidenbach - Oppenheimer

Boris Peaker - Cowen & Co., LLC

Mara Goldstein - Mizuho Securities

Avi Dahan - Truist Securities

Nick Abbott - Wells Fargo Securities

Carolina Ibanez Ventoso - Stifel Financial Corp.


Hello and welcome to the Iovance Biotherapeutics First Quarter 2021 Financial Results Conference. My name is Michelle and I will be the operator on today’s call. [Operator Instructions]

I will now turn the call over to Ms. Sara Pellegrino. Ma'am, you may begin.

Sara Pellegrino

Thank you, Operator. Good afternoon, and thank you for joining us. Speaking on today's call, we have Maria Fardis, our President and Chief Executive Officer; Friedrich Finckenstein, our Chief Medical Officer; and Jean-Marc Bellemin, our Chief Financial Officer. We are also joined by Jim Zigler, Senior Vice President, Commercial. This afternoon, we issued a press release that can be found on our website at iovance.com, which includes the financial results for the 3 months ended on March 31, 2021, as well as corporate update.

Before we start, I would like to remind everyone that statements made during this conference call will include forward-looking statements regarding Iovance's goals, business focus, business plans, pre-commercial activities, clinical trials and regulatory plans and results, potential future applications of our technologies, manufacturing capabilities, regulatory feedback and guidance, payer interaction, collaboration, cash position and expense guidance and future updates.

Forward-looking statements are subject to numerous risks and uncertainties, many of

Recommended For You


To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!

About IOVA

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on IOVA

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.